Randomized clinical trials for people with non-small cell lung cancer (NSCLC) often fail to capture some of the nuances of the condition that significantly impact the quality of life for people with the disease. Real-world data (RWD) can illuminate some of the hidden obstacles patients face, such as transportation challenges and lack of access to molecular testing. Pharma companies can analyze patient demographic and geographic data to strategically plan clinical trial sites that are more convenient for targeted patients.
A new eBook published by MedCity News for PurpleLab highlights how RWD and SDOH can lead to more inclusive clinical trials and drugs that improve the quality of life for larger, diverse patient populations not only for NSCLC, but other conditions as well. It discusses the patient experience, visualizing the continuum of care, breaking socio-economic barriers, social drivers of health data sources, biomarker testing innovation and legislation, and driving patient-centric innovation. RWD and SDOH data can also help drive greater market uptake and revenue.
To download the eBook, Eliminating Blind Spots in the Non-Small Cell Lung Cancer Patient Journey with RWD, please complete the form below.
Photo: Yuichiro Chino, Getty Images
